© 2020 Recharge Biomedical
Exosomes and TA-65 are not FDA-approved to prevent or treat any illness
In this 23-minute video, I explain how the FDA works. I explain the "minimally-altered" standard that regulates use of stem cells in the United States. The reason that the FDA will likely never cure aging and most chronic diseases is explained in terms of their modus operandi.
- Written:
- Author: Edward
- Posted in: dr ed park, economics, exosomes, fda
- Tags: Dr. Ed Park, drug approval, exosomes, exosomes7, fda, iron triangle, keytruda, kimera, off label, patient physician relationship
Reading Time: < 1 minute
The FDA. Exosomes Lecture 7 of 9
In this 23-minute video, I explain how the FDA works. I explain the “minimally-altered” standard that regulates use of stem cells in the United States. The reason that the FDA will likely never cure aging and most chronic diseases is explained in terms of their modus operandi.
The series covers the following topics:
Lecture 1: What are exosomes?
Lecture 2: Aging and exosomes
Lecture 3: Parabiosis and exosomes
Lecture 4: Cancer and exosomes
Lecture 5: A history of regenerative therapies in joints
Lecture 6: Are all exosomes created equal?
Lecture 7: The FDA
Lecture 8: What are the risks of exosomes?
Lecture 9: What is Dr. Park’s approach to exosomes?
If you are interested in learning more about the real life clinical anecdotes from exosome users, please email me directly at drpark@rechargebiomedical.com
I like to know each person who is receiving those private emails because I do not want those private blogs to be misconstrued as medical claims nor as advertising. I need your name, date of birth, a phone number, and a brief summary of why you are interested.
As a subscriber, you will have access to my password-protected blogs but you will need to add the above email to your email contacts to make sure they don’t go to spam.
